Oncology Brothers
LightNews LightNews
banner
oncbrothers.bsky.social
Oncology Brothers
@oncbrothers.bsky.social
790 followers 100 following 49 posts
Practice changing discussions by community oncologists: Drs. Rohit Gosain & Rahul Gosain. OwnViews/Not a Medical Advice.
COI http://bit.ly/3o9agL3
Web: http://oncbrothers.com
Posts Replies Media Videos
oncbrothers.bsky.social
#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇)

Full 🗣️:
⭐️ Oncbrothers.com/cabinet
⭐️ Also on the “Oncology Brothers” podcast

#OncSky #MedSky #GiOnc
April 10, 2025 at 10:02 PM
oncbrothers.bsky.social
Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice!

⭐️ InPerson: May 31st, 2025
⭐️ Location📍Marriott Marquis
⭐️ Time: 6:30-9:00PM
⭐️ Register bit.ly/aioasco25

#AdvInOnc25 #OncSky
April 7, 2025 at 2:23 AM
oncbrothers.bsky.social
#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara

Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast

#gism #CanSky #OncSky
February 22, 2025 at 4:34 PM
oncbrothers.bsky.social
Treatment Algorithm series: discussion on HER2+ #BreastCancer

✅ APT data/TCHP
✅ Metastatic disease
✅ Her2/ER/PR+

Full discussion:
⭐️ oncbrothers.com/her2positive...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast

#bcsm #CancerSky #OncSky

@drsarahsammons.bsky.social
February 18, 2025 at 2:16 AM
oncbrothers.bsky.social
Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social

✅ Early disease
✅ ≥T2 or N+ disease
✅ Metastatic disease
✅ Low ER/PR+

Full 🗣️:
⭐️ oncbrothers.com/how-to-treat...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast

#bcsm #BreastCancer
February 11, 2025 at 12:31 AM
oncbrothers.bsky.social
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:

- Bladder Ca
- Prostate Ca
- RCC

*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25

#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
February 6, 2025 at 11:23 PM
oncbrothers.bsky.social
AMPLIFY for 1L CLL now in @nejm.org

🔑 takeaways:

1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)

2️⃣ AVO showed deeper responses but higher infection risk

3️⃣ New SoC for many

#OncSky #CanSky #HemeSky
February 6, 2025 at 2:55 AM
oncbrothers.bsky.social
#GI25 highlights #CommunityOnc:

1. #SCIENCE: Adv Eso SCC

2. #ESOPEC publication (Eso/GEJ/Ga)

3. Chemo in resectable Panc Ca

4. #StarterNET: GEP-NET

5. #CM8HW: dMMR/MSI-H mCRC

6. #BREAKWATER: BRAFV600E mCRC

7. ctDNA: #BESPOKE + SWOG80702

#OncSky #gism @ascocancer.bsky.social

1/8
January 25, 2025 at 11:12 PM
oncbrothers.bsky.social
Datopotamab deruxtecan now #FDA approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC

- ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato)
- ⬆️ PFS 6.9mos vs 4.5 mos
- Better AE + QoL favoring DatoDXd
- AEs: Fatigue, infusion reactions, stomatitis

#bcsm #OncSky #MedSky
January 17, 2025 at 6:36 PM
oncbrothers.bsky.social
#GISeries: #Zanidatamab was recently approved based off #HerizonBTC01! We 🗣️ design, findings, sequencing and AEs/management with Dr. Shubham Pant

Full Discussion:
- Oncbrothers.com/zanidatamab-...
- Also on the “Oncology Brothers” podcast

#OncSky #MedSky #gism #GI25
January 3, 2025 at 1:28 AM
oncbrothers.bsky.social
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
oncbrothers.bsky.social
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:

1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib

#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
December 24, 2024 at 3:07 AM
oncbrothers.bsky.social
#Encorafenib + #Ceruximab + mFOLFOX is approved in 1L for BRAFV600e based off #BREAKWATER

- ORR 61% vs 40%
- mDoR: 13.9mos vs 11.1mos
- AEs:GI tox, rash

#cansky #oncsky #gism
December 21, 2024 at 12:36 PM
oncbrothers.bsky.social
🚨In 5 weeks it’s #GI25🚨 Let’s discuss the current SoC and how the new data will change/reinforce our practice at #AdvInOnc25:
- Upper GI
- CRC
- HepatoPanc & NET

**Join us LIVE**
📅 **Date**: Jan 24, 2025
⏰ **Time**: 6:00-8:00PM
Register here: bit.ly/aiogi25

#OncSky #CanSky #MedSky #GISM
December 20, 2024 at 5:20 PM
oncbrothers.bsky.social
Another ALK inhibitor (#ensartinib) gets FDA approval eXalt3 study:

- 1L, Ph III, ALK+ mNSCLC vs Crizotinib
- Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45)
- CNS ORR 64% w/ ensartinib vs 21%
- AES: rash, 💪 pain, nausea

#OncSky #MedSky #lcsm #CanSky
December 18, 2024 at 9:27 PM
oncbrothers.bsky.social
#GISeries: #Hepatocellular Ca 2/4: 2nd Line Treatment and when to switch!

🌟IO, TKIs, #supponc in 2L
🌟AEs/Management

Full 🗣️
- Oncbrothers.com/hcc-advanced...
- cor2ed.com/hcc-connect/...
- Also on “Oncology Brothers” podcast

#OncSky #MedSky #gism
@arndtvogel.bsky.social
December 14, 2024 at 12:40 PM
oncbrothers.bsky.social
5. #INSEMA: 🚫 of axillary ✂️ for SLNBx w/ clinically N-ve invasive breast cancer staged T1/T2 (≤5 cm) scheduled to undergo breast-conserving surgery.

- 5yr iDFS 91.9% without ✂️ vs 91.7%
- Omission of surgical axillary staging was noninferior to SLNBx

6/6
December 12, 2024 at 8:06 PM
oncbrothers.bsky.social
4. #SUPREMO: Selective Use of Postoperative Radiotherapy after Mastectomy:

- pT1N1M0, pT2N1M0, pT3N0M0, or pT2N0M0 Gr3 or LVI
- No 10 yr survival with XRT after mastectomy

5/6
December 12, 2024 at 8:06 PM
oncbrothers.bsky.social
3. #COMET: Ph 3, Active Monitoring With or Without ET for Low-Risk DCIS (HR+, Gr 1 or 2):

- Rate of ipsilateral invasive cancer 5.9% in the ET vs 4.2% in the active monitoring group
- At 2 yrs (short-term): active monitoring is not inferior to guideline-concordant care.

4/6
December 12, 2024 at 8:06 PM
oncbrothers.bsky.social
2. #PATINA: Ph 3, #palbociclib + Anti-HER2 + ET vs. anti-HER2 + ET after induction chemo for HR+ & HER2+ MBC:

- mPFS of 44.3mos w/ Palbo vs 29.1mos SoC (HR: 0.74)
- OS not mature yet
- New SoC for this subset
December 12, 2024 at 8:06 PM
oncbrothers.bsky.social
1. #EUROPA: Ph III, ET vs XRT after
surgery in ≥70 yrs HR+ luminal A-like early breast cancer. Median F/U: 2yrs

- Treatment-related AEs ⬇️ w/ XRT (67% vs 85%)
- ET was associated with a greater reduction in HRQOL but we need longer data for disease control

2/6
December 12, 2024 at 8:06 PM
oncbrothers.bsky.social
#SABCS24 Day 3 Highlights #CommunityOnc:

1. #EUROPA: ET vs XRT HR+ ≥70 yrs

2. #PATINA: CDK4/6 HR+ HER2+ new SoC

3. #COMET: DCIS

4. #SUPREMO: XRT post mastectomy

5. #INSEMA: ALNBx

@sabcs.bsky.social @theaacr.bsky.social
@drsarahsammons.bsky.social
@erikahamilton9.bsky.social
December 12, 2024 at 8:06 PM
oncbrothers.bsky.social
4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.

- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.

5/5
December 11, 2024 at 2:26 AM
oncbrothers.bsky.social
3. #DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow

- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??

4/5
December 11, 2024 at 2:26 AM
oncbrothers.bsky.social
2. #PADMA: Ph III, HR+ metastatic breast cancer, chemo vs ET + Palbociclib.

- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.

- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts

3/5
December 11, 2024 at 2:26 AM